Skip to main content

Table 1 Demographics of patients

From: Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC)

 

Demography

SCLC

LCNEC

Number/Median

%/Range

Number/Median

%/Range

Total patients

72,381

 

3496

 

Sex

 Male

36,406

50.30%

1928

55.15%

 Female

35,975

49.70%

1568

44.85%

Race

 White

63,192

87.30%

2919

83.50%

 Black

6284

8.68%

423

12.10%

 Other/unknown

2905

4.01%

154

4.41%

Total patients with SPM

1022

1.41%

139

3.98%

Sex

 Male

458

44.81%

68

48.92%

 Female

564

55.19%

71

51.08%

Race

 White

899

87.96%

113

81.29%

 Black

85

8.32%

19

13.67%

 Other/unknown

38

3.72%

7

5.04%

Patients with 1 SPM

862

1.20%

117

3.35%

Sex

 Male

384

44.55%

57

48.72%

 Female

478

55.45%

60

51.28%

Race

 White

755

87.59%

96

82.05%

 Black

74

8.58%

15

12.82%

 Other/unknown

33

3.83%

6

5.13%

Patients with 2 or more SPM

160

0.23%

22

0.63%

Sex

 Male

74

46.25%

11

50%

 Female

86

53.75%

11

50%

Race

 White

143

89.38%

17

77.27%

 Black

12

7.50%

4

18.18%

 Other/unknown

5

3.12%

1

4.55%

Age for SPM (median)

64 years

(36-88 years)

66 years

(37-82 years)

Latency (median)

3.58 years

(0.5–16.42 years)

3.33 years

(0.67-15 years)

Follow-up (median)

5.42 years

(0.5–16.92 years)

5.92 years

(0.67–15.75 years)